Maintenance Pembrolizumab and Radiotherapy Improve Outcomes in Oligometastatic Renal Cell Carcinoma

The management of metastatic renal cell carcinoma relies heavily on immune checkpoint inhibitors, yet achieving durable responses remains a challenge for many patients [1, 2]. In the oligometastatic setting, where patients present with a limited number of lesions, radiotherapy-based metastasis-directed therapy has emerged as a viable strategy to achieve local control and potentially defer the initiation of continuous systemic agents [3, 4]. While local ablation can provide excellent site-specific success, the optimal timing and integration of systemic immunotherapy to prevent distant progression are not yet fully defined [5, 6]. Clinicians must balance the benefits of aggressive local intervention with the need for systemic surveillance to address subclinical disease [7, 8]. A recent exploratory cohort study offers fresh insights into how combining these two modalities may alter the clinical trajectory and immune landscape for this patient population.